- Home
- ME vs TLSI Comparison
ME vs TLSI Comparison
Compare ME & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- TLSI
- Stock Information
- Founded
- ME 2006
- TLSI 2010
- Country
- ME United States
- TLSI United States
- Employees
- ME N/A
- TLSI N/A
- Industry
- ME Precision Instruments
- TLSI Medical Specialities
- Sector
- ME Health Care
- TLSI Health Care
- Exchange
- ME Nasdaq
- TLSI Nasdaq
- Market Cap
- ME 168.9M
- TLSI 166.8M
- IPO Year
- ME N/A
- TLSI N/A
- Fundamental
- Price
- ME $0.34
- TLSI $4.62
- Analyst Decision
- ME Hold
- TLSI Strong Buy
- Analyst Count
- ME 1
- TLSI 3
- Target Price
- ME $0.47
- TLSI $12.67
- AVG Volume (30 Days)
- ME 2.4M
- TLSI 72.3K
- Earning Date
- ME 11-06-2024
- TLSI 11-12-2024
- Dividend Yield
- ME N/A
- TLSI N/A
- EPS Growth
- ME N/A
- TLSI N/A
- EPS
- ME N/A
- TLSI N/A
- Revenue
- ME $199,188,000.00
- TLSI $24,736,000.00
- Revenue This Year
- ME $0.05
- TLSI $61.24
- Revenue Next Year
- ME $17.98
- TLSI $47.32
- P/E Ratio
- ME N/A
- TLSI N/A
- Revenue Growth
- ME N/A
- TLSI 67.75
- 52 Week Low
- ME $0.29
- TLSI $3.32
- 52 Week High
- ME $1.09
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- ME 49.74
- TLSI 35.17
- Support Level
- ME $0.29
- TLSI $4.54
- Resistance Level
- ME $0.36
- TLSI $5.08
- Average True Range (ATR)
- ME 0.02
- TLSI 0.35
- MACD
- ME 0.01
- TLSI -0.04
- Stochastic Oscillator
- ME 64.86
- TLSI 18.66
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.